Lactose engineering for better performance in dry powder inhalers

Advanced Pharmaceutical Bulletin

Volumn 2, Issue 2, 2012, Pages 183-187

  Rahimpour, Yahya ^a   Hamishehkar, Hamed ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carrier; Dry powder inhaler; Lactose; Pulmonary drug delivery

Indexed keywords

CARBOMER; CORTICOSTEROID; DRUG CARRIER; LACTOSE; MANNITOL; PRANLUKAST; SALBUTAMOL SULFATE;

ARTICLE; ASTHMA; BIODEGRADABILITY; BIOENGINEERING; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; EXCIPIENT COMPATIBILITY; HUMAN; IN VITRO STUDY; METERED DOSE INHALER; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; SPRAY DRYING; SURFACE PROPERTY;

EID: 84875912337     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2012.028     Document Type: Article

References (44)

1. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 1994;101(1-2):1-13.
2. Todo H, Okamoto H, Iida K, Danjo K. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int J Pharm 2001;220:101-10.
3. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 1997;14:969-75.
4. Prime D, Atkins PJ, Slater A, Sumby B. Review of dry powder inhalers. Adv Drug Deliv Rev 1997;26(1):51-8.
5. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, et al. Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules. Powder Technol 2010;201: 289-95.
6. Marriott C, Frijlink HW. Lactose as a carrier for inhalation products: breathing new life into an old carrier. Adv Drug Deliv Rev 2012;64(3):217-9.
7. Atkins PJ. Dry powder inhalers: an overview. Resp Care 2005;50(10):1304-12.
8. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Hassanzadeh K, et al. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharm Drug Dispos 2010;31(2-3):189-201.
9. Geller DE, Konstan WK, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulm 2007;42:307-13.
10. Hickey AJ, Lu D, Ashley ED, Stout J. Inhaled azithromycin therapy. J Aerosol Med 2006;19:54-60.
11. Stoessl AJ. Potential therapeutic targets for Parkinson's disease. Expert Opin Ther Tar 2008;12:425-36.
12. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm 2009;369(1-2):136-43.
13. Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release 2008;128(3):224-32.
14. Farr SJ, Otulana BA. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev. 2006;58(9):1076-88.
15. Kleinstreuer C, Zhang Z, Donohue JF. Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng 2008;10:195-220.
16. Fleischer W, Reimer K, Leyendecker P. Opioids for the treatment of the chronic obstructive pulmonary disease. Luxembourg: Euro-Celtique S.A; 2005.
17. Ali R, Jain GK, Iqbal Z, Talegaonkar S, Pandit P, Sule S, et al. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine 2009;5(1):55-63.
18. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2002;19(3):239-45.
19. Wolff RK, Dorato MA. Toxicologic testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol 1993;23:343-69.
20. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58(9):1030-60.
21. Emami J, Hamishehkar H, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, et al. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J Microencapsul 2009;26(1):1-8.
22. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-5 μm. J Aerosol Sci 1986;17(5):811-25.
23. Pilcer G, Wauthoz N, Amighi K. Lactose characteristics and the generation of the aerosol. Adv Drug Deliv Rev 2012;64: 233-56.
24. Iida K, Hayakawa Y, Okamoto H, Danjo K, Luenberger H. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem Pharm Bull 2003;51(12):1455-7.
25. Schiavone H, Palakodaty S, Clark A, York P, Tzannis ST. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm 2004;281(1):55-66.
26. Iida K, Hayakawa Y, Okamoto H, Danjo K, Leuenberger H. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Chem Pharm Bull 2001;49(10):1326-30.
27. Zeng XM, Pandhal KH, Martin GP. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int J Pharm 2000;197:41-52.
28. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, et al. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin. Int J Pharm 2010;389(1-2):74-85.
29. Zeng XM, Martin GP, Marriott C, Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 2000;200:93-106.
30. Zhou QT, Morton DAV. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder Inhaler formulations by altering lactose carrier surfaces. Adv Drug Deliv Rev 2012;64(3):275-84.
31. Zeng XM, Martin GP, Marriott C, Pritchrd J. The Influence of crystallization conditions on the morphology of lactose intended for use as a carrier for dry powder aerosols. J Pharm Pharmacol 2000;52:633-43.
32. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):600-12.
33. Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 2004;270(1):297-306.
34. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010;392:1-19.
35. Iida K, Hayakawa Y, Okamoto H, Danjo K, Leuenberger H. Preparation of dry powder inhalation by surface treatment of lactose carrier particles. Chem Pharm Bull 2003;51(1):1-5.
36. Chan LW, Lim LT, Heng PWS. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations. J Pharm Sci 2003;92(5):975-84.
37. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm 1998;172(1):179-88.
38. Iida K, Todo H, Okamoto H, Danjo K, Leuenberger H. Preparation of dry powder inhalation with lactose carrier particles surface-coated using a Wurster fluidized bed. Chem Pharm Bull 2005;53(4):431-4.
39. Iida K, Hayakawa Y, Okamoto H, Danjo K, Luenbergerb H. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem Pharm Bull 2004;52 (3):350-3.
40. Littringer EM, Mescher A, Schroettner H, Achelis L, Walzel P, Urbanetz NA. Spray dried mannitol carrier particles with tailored surface properties -The influence of carrier surface roughness and shape. Eur J Pharm Biopharm 2012;82(1):194-204.
41. Zeng XM, Martin GP, Marriott C, Pritchard J. The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate. Eur J Pharm Biopharm 2001;51(1):55-62.
42. Zeng XM, Martin GP, Marriott C, Pritchard J. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J Pharm Sci 2001;90(9):1424-34.
43. Young PM, Kwok P, Adi H, Chan H-K, Traini D. Lactose composite carriers for respiratory delivery. Pharm Res 2009;26(4):802-10.
44. Kaialy W, Larhrib H, Martin GP, Nokhodchi A. The effect of engineered mannitol-lactose mixture on dry powder inhaler performance. Pharm Res 2012; 29(3):2139-56.